Weekly updates from the National Comprehensive Cancer Network share every time a change is made to evidence-based, expert consensus-driven guidelines…
This positive CHMP opinion is based on results from the Phase 3 BREAKWATER trial, which showed that encorafenib in combination…
MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular…
Sheridan, WY, May 07, 2026 (GLOBE NEWSWIRE) -- Compounded medications are not FDA-approved finished drug products. Novi connects eligible adults…
NEW DELHI, April 30, 2026 /PRNewswire/ -- The Partnership to Fight Chronic Disease (PFCD) convened a panel of leading orthopaedic…
Nxera’s partner Holling Bio-Pharma Corp. will commercialize QUVIVIQ® in Taiwan, a market with approximately 4–5 million patients, with launch planned during 2026QUVIVIQ®…
April 10, 2026 17:02 ET | Source: Replimune, Inc. WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc.…
Boise, ID, April 03, 2026 (GLOBE NEWSWIRE) -- This release is based on information provided by Blue Heron Health News…
Johnson & Johnson presents findings from the largest European real-world dataset for esketamine nasal spray (NS) which confirm its effectiveness…
HONG KONG, March 12, 2026 /PRNewswire/ -- Approximately 40% of the East Asian population suffers from alcohol intolerance, commonly known…